GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » Debt-to-Asset

Voyageur Pharmaceuticals (TSXV:VM) Debt-to-Asset : 0.02 (As of May. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals Debt-to-Asset?

Voyageur Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was C$0.00 Mil. Voyageur Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was C$0.04 Mil. Voyageur Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in May. 2024 was C$2.33 Mil. Voyageur Pharmaceuticals's debt to asset for the quarter that ended in May. 2024 was 0.02.


Voyageur Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Voyageur Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals Debt-to-Asset Chart

Voyageur Pharmaceuticals Annual Data
Trend Dec14 Dec15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.21 0.02 0.01 0.02

Voyageur Pharmaceuticals Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.02 0.02 0.02

Competitive Comparison of Voyageur Pharmaceuticals's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Debt-to-Asset falls into.



Voyageur Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Voyageur Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Nov. 2023 is calculated as

Voyageur Pharmaceuticals's Debt-to-Asset for the quarter that ended in May. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyageur Pharmaceuticals  (TSXV:VM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Voyageur Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyageur Pharmaceuticals Business Description

Traded in Other Exchanges
Address
333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1
Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.
Executives
Charles Littlejohn 10% Security Holder

Voyageur Pharmaceuticals Headlines

No Headlines